Cargando…
Modulation of Type I Interferon Responses to Influence Tumor-Immune Cross Talk in PDAC
Immunotherapy has revolutionized the treatment of many cancer types. However, pancreatic ductal adenocarcinomas (PDACs) exhibit poor responses to immune checkpoint inhibitors with immunotherapy-based trials not generating convincing clinical activity. PDAC tumors often have low infiltration of tumor...
Autores principales: | Cattolico, Carlotta, Bailey, Peter, Barry, Simon T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902310/ https://www.ncbi.nlm.nih.gov/pubmed/35273962 http://dx.doi.org/10.3389/fcell.2022.816517 |
Ejemplares similares
-
Opposite Roles of Tumor Cell Proliferation and Immune Cell Infiltration in Postoperative Liver Metastasis of PDAC
por: Wang, Guangfu, et al.
Publicado: (2021) -
Cell Lineage Infidelity in PDAC Progression and Therapy Resistance
por: Malinova, Antonia, et al.
Publicado: (2021) -
PDAC as an Immune Evasive Disease: Can 3D Model Systems Aid to Tackle This Clinical Problem?
por: Narayanan, Shruthi, et al.
Publicado: (2021) -
Identification of DDX31 as a Potential Oncogene of Invasive Metastasis and Proliferation in PDAC
por: Xie, Yongjie, et al.
Publicado: (2022) -
Tumor-Stroma Interaction in PDAC as a New Approach for Liquid Biopsy and its Potential Clinical Implications
por: Götze, Julian, et al.
Publicado: (2022)